Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00668395 · ClinicalTrials.gov registry record · NA

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

A NA study of HIV, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
73
Enrollment target
2
Study locations

NCT00668395 is a NA study of HIV that has completed, run by Indiana University. The registered enrollment target is 73 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00668395, a NA study of HIV, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target
2
Study locations

Study Summary

1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get rid of efavirenz from your body. This may render efavirenz and other medications ineffective. 2. To see how efavirenz interact with other drugs taken at the same time with it. 3. To see if genetic differences can change the way how the liver breaks down efavirenz and its interactions with other co-administered drugs.

Conditions Studied

Interventions

  • DRUG Efavirenz

Study Locations (2)

Indiana

  • Indiana Clinical Research Center (ICRC) - Indianapolis
  • Indiana University - Indianapolis

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2007-05
Est. Completion 2010-04
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT00668395

The ClinicalTrials.gov registry entry for NCT00668395 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Efavirenz is the first listed.

NCT00668395 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00668395 about?

NCT00668395 is a clinical study titled "Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics". 1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get rid of efavirenz from your body. This may render efavirenz and other medi...

What is the current status of trial NCT00668395?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2007-05. Estimated completion is 2010-04.

What conditions does trial NCT00668395 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT00668395?

The interventions under investigation include: Efavirenz (DRUG).

Who is sponsoring clinical trial NCT00668395?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00668395 being conducted?

This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.